Ehna

Ehna

SCHEMBL1742893

CCCCCC[C@@H]([C@@H](C)O)n1cnc2c(N)ncnc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADA P00813 6/20 1.00
PDE2A O00408 3/20 1.00
CYP3A4 P08684 2/20 1.00
PDE4A P27815 1/20 1.00
PDE4B Q07343 1/20 1.00
PDE4C Q08493 1/20 1.00
PDE4D Q08499 1/20 1.00
KDM4E B2RXH2 1/20 1.00
ALDH1A1 P00352 1/20 1.00
CYP1A2 P05177 1/20 1.00
ALOX15 P16050 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HSD17B10 Q99714 1/20 1.00
TSHR P16473 1/20 1.00
HIF1A Q16665 1/20 1.00
LMNA P02545 1/20 0.98
BLM P54132 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Ehna SCHEMBL1742728 1.00 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL1740490 1.00 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL14985129 1.00 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL29481903 0.99 PDE2A (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL14975587 0.99 PDE2A (1.00) ADAPDE2ACYP3A4PDE4APDE4B
Ehna SCHEMBL29391683 0.99 PDE2A (1.00) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL1740514 0.99 ADA (0.98) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL9083113 0.90 ADA (0.82) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL9083109 0.90 ADA (0.82) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL8585722 0.90 ADA (0.82) ADAPDE2ACYP3A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
US-20230098694-A1 NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS ITEOS BELGIUM S A (BE) 2023-03-30 US disclosed
US-11427594-B2 Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers iTeos Belgium SA (BE) 2022-08-30 US disclosed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-8569481-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PHARMACEUTICALS, INC. (US) 2013-10-29 US disclosed
US-20120202287-A1 Stem Cell Culture Methods ITI SCOTLAND LIMITED (GB) 2012-08-09 US disclosed
EP-2389436-A2 STEM CELL CULTURE METHODS ITI Scotland Limited (GB) 2011-11-30 EP disclosed
US-20110257911-A1 SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING JOHNSON CONTROLS TECHNOLOGY COMPANY 2011-10-20 US disclosed
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions KOESTER HUBERT 2011-05-19 US disclosed
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
WO-2010084300-A2 STEM CELL CULTURE METHODS ITI SCOTLAND LIMITED (GB) 2010-07-29 WO disclosed
EP-0633772-A1 MEDICAMENT AGAINST CARDIAC CIRCULATORY DISEASES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1995-01-18 EP disclosed
WO-1993019742-A1 MEDICAMENT AGAINST CARDIAC CIRCULATORY DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1993-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PTMS, QPCTL, SRMS ADA 3561/4885PDE2A 4595/4885CYP3A4 3746/4885
US-11427594-B2 Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers ADORA2A, ADORA2B, ADORA1 ADA 194/4885PDE2A 200/4885CYP3A4 2677/4885
US-20230098694-A1 NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS ADORA2A, ADORA2B, ADORA1 ADA 194/4885PDE2A 200/4885CYP3A4 2677/4885
US-20120202287-A1 Stem Cell Culture Methods KIT, SOX18, MCL1 ADA 4438/4885PDE2A 3669/4885CYP3A4 4330/4885
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers ADORA2A, ADORA2B, ADORA3 ADA 499/4885PDE2A 252/4885CYP3A4 611/4885
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CHLSN, PTMS, SRMS ADA 3803/4885PDE2A 4462/4885CYP3A4 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.